EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scopus BioPharma's enterprise value is $-0.32 Mil.
Scopus BioPharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-9.34 Mil. Therefore, Scopus BioPharma's EV-to-EBITDA for today is 0.03.
The historical rank and industry rank for Scopus BioPharma's EV-to-EBITDA or its related term are showing as below:
SCPS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.39 Med: 0 Max: 0.36
Current: 0.03
During the past 6 years, the highest EV-to-EBITDA of Scopus BioPharma was 0.36. The lowest was -47.39. And the median was 0.00.
SCPS's EV-to-EBITDA is ranked better than 96.16% of 469
companies
in the Biotechnology industry
Industry Median: 9.09
vs SCPS: 0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Scopus BioPharma EV-to-EBITDA Historical Data
The historical data trend for Scopus BioPharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scopus BioPharma's EV-to-EBITDA
For the Biotechnology subindustry, Scopus BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scopus BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scopus BioPharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scopus BioPharma's EV-to-EBITDA falls into.
Scopus BioPharma's current Enterprise Value is $-0.32 Mil.
Scopus BioPharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Scopus BioPharma's PE Ratio for today is calculated as:
Scopus BioPharma's share price for today is $0.0011.
Scopus BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Scopus BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Scopus BioPharma (Scopus BioPharma) Business Description
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCPS has been successfully added to your 